前列腺癌放疗:SBRT推量对比HDR近距离推量的倾向评分匹配分析
单机构回顾性分析比较盆腔外照射联合SBRT推量(21 Gy和19 Gy分2次)与HDR近距离推量(19 Gy分2次)治疗局限期前列腺癌。中位随访分别为73.4和186.0个月,倾向评分匹配及多因素Cox回归显示两组生化复发无进展生存和转移无进展生存均无显著差异,3级以上泌尿生殖和胃肠毒性均较低。
要点
- SBRT推量组与HDR推量组在调整协变量后BCRF和MF均无显著差异。
- 倾向评分匹配后两组BCRF(HR 0.66)和MF(HR 0.84)差异仍无统计学意义。
- SBRT组3级以上泌尿生殖毒性和胃肠毒性分别为4.6%和1.5%。
核心结论
- 在本单机构倾向评分匹配回顾性分析中,盆腔外照射联合SBRT推量治疗前列腺癌的BCRF和MF与HDR推量相似,毒性适中。
研究设计与样本
- 单机构回顾性病历分析,比较盆腔外照射联合SBRT推量(21 Gy和19 Gy分2次)与HDR近距离推量(19 Gy分2次)治疗的前列腺癌患者。
- 采用倾向评分匹配和多因素Cox回归分析,结局为生化复发无进展生存(BCRF)和转移无进展生存(MF)。
主要发现
- 68.8%患者为高危、26.0%为不利中间风险,94.3%接受雄激素剥夺治疗。
- SBRT组5年和10年未调整BCRF为88.8%和85.3%,HDR组为91.8%和74.6%(log-rank P = .3)。
- SBRT组5年和10年未调整MF为91.7%和84.3%,HDR组为95.8%和82.0%(log-rank P = .8)。
- 调整协变量后BCRF的HR为0.81(95%CI 0.37-1.79,P = .6),MF的HR为1.07(95%CI 0.44-2.57,P = .9)。
- 倾向评分匹配后BCRF的HR为0.66(95%CI 0.27-1.62,P = .4),MF的HR为0.84(95%CI 0.31-2.26,P = .7)。
关键数值与推荐
- SBRT组3级以上泌尿生殖毒性和胃肠毒性分别为4.6%和1.5%,HDR组分别为3.0%和0.0%(P = .4,Fisher精确检验)。
临床怎么用
- 对于不利中间风险和高危前列腺癌,SBRT推量联合盆腔外照射可作为HDR推量的潜在替代方案,但需前瞻性研究验证。
局限性
- 单机构回顾性设计,两组随访时间差异较大,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To perform a propensity-score matched analysis comparing stereotactic body radiation therapy (SBRT) boost and high-dose-rate (HDR) boost for localized prostate cancer. METHODS AND MATERIALS: A single-institution retrospective chart review was conducted of men treated with pelvic external beam radiation therapy (EBRT) and SBRT boost (21 Gy and 19 Gy in 2 fractions) to the prostate for prostate cancer. A cohort treated at the same institution with HDR brachytherapy boost (19 Gy in 2 fractions) was compared. Propensity-score (PS) matching and multivariable Cox regression were used for analysis. Outcomes were biochemical recurrence freedom (BCRF) and metastasis freedom (MF). RESULTS: One hundred thirty-one men were treated with SBRT boost and 101 with HDR boost with median follow-up of 73.4 and 186.0 months, respectively. In addition, 68.8% of men had high-risk and 26.0% had unfavorable-intermediate disease, and 94.3% received androgen deprivation therapy. Five- and 10-year unadjusted BCRF was 88.8% and 85.3% for SBRT and 91.8% and 74.6% for HDR boost (log-rank P = .3), and 5- and 10-year unadjusted MF was 91.7% and 84.3% for SBRT and 95.8% and 82.0% for HDR (log-rank P = .8). After adjusting for covariates, there was no statistically significant difference in BCRF (hazard ratio [HR] 0.81; 95% confidence interval [CI], 0.37-1.79; P = .6) or MF (HR 1.07; 95% CI, 0.44-2.57; P = .9) between SBRT and HDR boost. Similarly, after PS matching, there was no statistically significant difference between SBRT and HDR (BCRF: HR 0.66, 0.27-1.62, P = .4; MF: HR 0.84, 0.31-2.26, P = .7). Grade 3+ genitourinary and gastrointestinal toxicity in the SBRT cohort were 4.6% and 1.5%, and 3.0% and 0.0% in the HDR cohorts (P = .4, Fisher exact test). CONCLUSIONS: SBRT boost plus pelvic EBRT for prostate cancer resulted in similar BCRF and MF to HDR boost in this single institution, PS matched retrospective analysis. Toxicity was modest. Prospective evaluation of SBRT boost for the treatment of unfavorable-intermediate and high-risk prostate cancer is warranted.
引用
- Chen WC, Li Y, Lazar A, et al. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis. Int J Radiat Oncol Biol Phys. 2020. PMID: 33385496. doi:10.1016/j.ijrobp.2020.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。